Category survey

Protein damage control: regulation of toxic protein aggregation in aging-associated neurodegenerative diseases Investments > €500k European Commission Neurodegenerative disease in general 2016    

NOX enzymes as mediators of inflammation-triggered neurodegeneration: modulating NOX enzymes as novel therapies Investments > €500k European Commission Neurodegenerative disease in general 2016    

Improving Translational Research Potential at the Institute of Biomedicine of Seville Investments > €500k European Commission Neurodegenerative disease in general 2016    

Virtual, Physiological and Computational Neuromuscular Models for the Predictive Treatment of Parkinson’s Disease Investments > €500k European Commission Parkinson’s disease & PD-related disorders 2016    

Protease Systems Biology in Tumorigenesis and Neurodegeneration Investments > €500k European Commission Neurodegenerative disease in general 2016    

Imaging of Neuroinflammation in Neurodegenerative Diseases Investments > €500k European Commission Neurodegenerative disease in general 2016    

Perineuronal net treatments for neurodegenerative disease Investments > €500k European Commission Alzheimer’s disease & other dementias 2016    

VPH Dementia Research Enabled by IT Investments > €500k European Commission Alzheimer’s disease & other dementias 2016    

A European multicentre double-blind placebo-controlled phase III trial of nilvadIpine in mild to moderate Alzheimer’s disease Investments > €500k European Commission Alzheimer’s disease & other dementias 2016    

SYSTEMS BIOLOGY OF PATHWAYS INVOLVING BRAIN AGEING Investments > €500k European Commission Alzheimer’s disease & other dementias 2016    

Mapping the late-life health promoting mechanisms in worms and mammals Investments > €500k European Commission Neurodegenerative disease in general 2016    

Evolution of Alzheimer’s Disease: From dynamics of single synapses to memory loss Investments > €500k European Commission Alzheimer’s disease & other dementias 2016    

Integrated European –omics research project for diagnosis and therapy in rare neuromuscular and neurodegenerative diseases Investments > €500k European Commission Neurodegenerative disease in general 2016    

Human pluripotent stem cell differentiation, safety and preparation for therapeutic transplantation in Huntington’s disease Investments > €500k European Commission Huntington’s disease|Parkinson’s disease & PD-related disorders 2016    

European stem cell consortium for neural cell replacement, reprogramming and functional brain repair Investments > €500k European Commission Huntington’s disease|Parkinson’s disease & PD-related disorders 2016    

Reach α-synuclein-dependent neurodegeneration: clinical development of therapeutic AFFITOPE vaccines for Parkinson’s disease and multisystem atrophy Investments > €500k European Commission Parkinson’s disease & PD-related disorders 2016    

Gene therapy and nanotechnology based CNS targeted vectors Investments > €500k European Commission Motor neurone diseases|Spinal muscular atrophy (SMA) 2016    

Simulation of the Kinetics and Inverse Problemfor the Protein PolymERizationin Amyloid Diseases (Prion, Alzheimer’s) Investments > €500k European Commission Alzheimer’s disease & other dementias|Prion disease 2016    

European Medical Information Framework (EMIF) Investments > €500k European Commission Alzheimer’s disease & other dementias 2016    

Cell Biology: Cellular functions of the prion protein Investments > €500k United Kingdom Prion disease 2016    

HTS – Maximising the value of MRC Brain Banks Investments > €500k United Kingdom Neurodegenerative disease in general 2016    

Reducing pathology in Alzheimer’s Disease through Angiotensin TaRgeting – The RADAR Trial Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016    

Minocycline in Alzheimer’s Disease Efficacy Trial: The MADE Trial Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016    

Interactions within and between the basal ganglia and thalamocortical circuits in function and dysfunction Investments > €500k United Kingdom Parkinson’s disease & PD-related disorders 2016    

Mental Ageing Investments > €500k United Kingdom Alzheimer’s disease & other dementias|Neurodegenerative disease in general 2016    

Neuronal model systems and neurotoxicity Investments > €500k United Kingdom Neurodegenerative disease in general 2016    

Temporally patterned closed-loop stimulation for therapy of brain disorders Investments > €500k United Kingdom Parkinson’s disease & PD-related disorders 2016    

Measuring Recollection and Familiarity in Ageing and Mild Cognitive Impairment Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016    

Selecting Futures: The Social and Ethical Implications of Genetic Screening Investments > €500k United Kingdom Spinal muscular atrophy (SMA) 2016    

Analysis of mitochondrial homeostasis in ageing and neurodegeneration Investments > €500k United Kingdom Motor neurone diseases|Neurodegenerative disease in general|Parkinson’s disease & PD-related disorders 2016    

Using computer simulations for predicting interventions restoring healthy patterns of neural activity Investments > €500k United Kingdom Parkinson’s disease & PD-related disorders 2016    

European multidisciplinary ALS network identification to cure motor neuron degeneration Investments > €500k European Commission Motor neurone diseases 2016    

Role of microRNA dysregulation in Alzheimers Disease Investments > €500k European Commission Alzheimer’s disease & other dementias 2016    

Prion-like transmission of α-synuclein in Parkinson’s disease Investments > €500k European Commission Parkinson’s disease & PD-related disorders 2016    

NEURAL TRANSPLANTATION IN THE TREATMENT OF PATIENTS WITH PARKINSON’S DISEASE Investments > €500k European Commission Parkinson’s disease & PD-related disorders 2016    

Improving the lives of Parkinson’s Disease patients while reducing side-effects through tailored deep brain stimulation Investments > €500k European Commission Parkinson’s disease & PD-related disorders 2016    

NEUROACT: A collaborative training program to develop multi-electrode array (MEA) platforms to understand synaptic function and treat diseases of the nervous system Investments > €500k European Commission Neurodegenerative disease in general 2016    

Cell death regulation Investments > €500k United Kingdom Neurodegenerative disease in general 2016    

Cellular mechanisms of prion propagation Investments > €500k United Kingdom Prion disease 2016    

Transmissible disease epidemiology & statistical science in public health, criminal justice & performance monitoring Investments > €500k United Kingdom Prion disease 2016    

Molecular diagnostic strategies in prion disease Investments > €500k United Kingdom Prion disease 2016    

Clinical Research Studies in the UK and PNG Investments > €500k United Kingdom Prion disease 2016    

Structural studies of prion proteins and their ligand interactions Investments > €500k United Kingdom Prion disease 2016    

Molecular and phenotypic analysis of human prion strains Investments > €500k United Kingdom Prion disease 2016    

Transgenic modelling of human prion diseases, intermammalian transmission barriers & assessing candidate therapeutics Investments > €500k United Kingdom Prion disease 2016    

Prion genetic modifiers in the mouse Investments > €500k United Kingdom Prion disease 2016    

Human molecular genetics and bioinformatics Investments > €500k United Kingdom Prion disease 2016    

Molecular mechanisms of neurodegeneration Investments > €500k United Kingdom Alzheimer’s disease & other dementias|Parkinson’s disease & PD-related disorders 2016    

Cellular aspects of protein misfolding in neurodegenerative diseases Investments > €500k United Kingdom Neurodegenerative disease in general 2016    

Prion kinetics, toxicity and synthesis and its wider relevance Investments > €500k United Kingdom Prion disease 2016